I have had an interest in pediatric endocrine pathophysiology since medical school. I’m attracted to this field because of the treatment courses I am able to be a part of with families.
As a pediatric endocrinologist, I have a special interest in neuro-oncology, which pertains to the endocrine needs of patients who have cancers of the brain or spinal cord. I also treat patients with septo-optic dysplasia, which is a disorder of early brain development that involves the optic nerves and other brain structures.
Neuro-oncology and septo-optic dysplasia require a multidisciplinary approach, and patients with these conditions connect with physicians in multiple specialties. This team approach allows for consistent communication among providers and with the patient and family. With every patient and family, I strive to provide exceptional care.
In my research, I am involved in studies pertaining to my clinical interests (neuro-oncology and septo-optic dysplasia), as well as quality improvement and how it pertains to inpatient care. I am specifically looking at ways to decrease adverse events with high-risk medications such as insulin. My research has resulted in the development of the Diabetes Day Hospital Program, a reduction in inpatient insulin errors throughout the institution, and the continuation of home insulin pumps during hospitalizations.
When I’m not working with patients, I enjoy spending time with my family and sewing. I also take care of my dog, who has diabetes.
MD: University of Kentucky, Lexington, KY.
Residency: Kentucky Children’s Hospital, Lexington, KY.
Fellowship: Cincinnati Children’s Hospital, Cincinnati, OH.
Pediatric endocrinology; septo-optic dysplasia; endocrine disease related to brain tumors; inpatient delivery of diabetes care
Endocrinology, Brain Tumor
Septo-optic dysplasia; endocrine disease related to brain tumors; inpatient delivery of diabetes care
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
An Initiative to Reduce Insulin-Related Adverse Drug Events in a Children's Hospital. Pediatrics. 2022; 149:e2020004937.
Improved Glycemic Outcomes with Early Initiation of Insulin Pump Therapy in Pediatric Postoperative Total Pancreatectomy with Islet Autotransplantation. Journal of Clinical Medicine. 2021; 10:2242.
Inaccurate Glucose Sensor Values After Hydroxyurea Administration. Diabetes Technology and Therapeutics. 2021; 23:443-451.
Continuous Glucose Monitoring in the Intensive Care Unit Following Total Pancreatectomy with Islet Autotransplantation in Children: Establishing Accuracy of the Dexcom G6 Model. Journal of Clinical Medicine. 2021; 10:1893.
Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor. Journal of Pediatric Hematology/Oncology. 2021; 43:e550-e553.
Progression of Vasculopathy in Young Individuals with Turner Syndrome. Pediatric Cardiology. 2021; 42:481-491.
A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Journal of Neuro-Oncology. 2020; 149:511-522.
115-OR: Early Insulin Pump Use in Pediatric Post–Total Pancreatectomy Islet Auto Transplantation Management. Diabetes. 2020; 69.
903-P: Hydroxyurea Resulting in False Elevation of Continuous Glucose Sensor Values. Diabetes. 2020; 69.
Assessment of a Day Hospital Management Program for Children With Type 1 Diabetes. JAMA Network Open. 2020; 3:e200347.